ALX Oncology Holdings Inc. Q3 2025 Earnings Recap

ALXO Q3 2025 November 8, 2025

Get alerts when ALXO reports next quarter

In Q3 2025, the company achieved significant progress in its clinical programs with robust data highlighting the role of CD47 as a predictive biomarker for evorpacept, positioning it favorably in the oncology landscape.

Earnings Per Share Miss

$-0.41 vs $-0.37 est.

-10.8% surprise

Market Reaction

1-Day +0.0%

5-Day -11.59%

30-Day -4.35%

See ALXO alongside your other holdings

Add to your portfolio — free

Key Takeaways

Presenting compelling Phase II data at SITC underscoring CD47 expression as a key biomarker for enhanced response in HER2-positive gastric cancer patients treated with evorpacept.
Strong clinical outcomes: ORR of 65% and median PFS of over 18 months for patients with high CD47 expression, well outperforming the control group.
Cash reserves of $67 million expected to sustain operations through Q1 2027, supporting ongoing clinical development milestones.
Initial patient dosing in the Phase I trial of ALX2004 completed, with expected safety data in H1 2026.
Focused strategy to drive value-enhancing data from both evorpacept and ALX2004 is on track, with key milestones anticipated in 2026.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit ALXO on AllInvestView.

Next Q1 2026